Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of MACI for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea

Next Previous
Trial Profile

An Extension Protocol for Participants of Genzyme-Sponsored Prospective, Randomized, Open-Label, Parallel-Group, Multicenter Study of MACI for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle Including the Trochlea

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous cultured chondrocytes (Primary)
  • Indications Cartilage disorders
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation; Vericel Corporation

    • Most Recent Events

    • 23 Mar 2018 According to a Vericel Corporation media release, results were published in the American Journal of Sports Medicine.
    • 10 May 2016 According to a Vericel Corporation media release, the US FDA has accepted for review the BLA for MACI with a PDUFA goal date of January 3, 2017.
    • 14 Mar 2016 According to a Vericel Corporation media release, the US FDA has accepted for filing a Biologics License Application (BLA) for MACI for the treatment of symptomatic cartilage defects of the knee in adults.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top